CAJ | 학술논문

目的：观察131I-CD133mAb在体内外对高表达CD133抗原的Huh-7人肝癌细胞的靶向抑制作用。方法采用氯胺T法制备并鉴定131I-CD133mAb；流式检测Huh-7和HepG2细胞中CD133的表达，免疫组化检测瘤体内CD133的表达；实验设131I-CD133mAb与顺铂（cisplatin, DDP）联用组、131I-CD133mAb组、DDP组及空白对照组。MTT法检测各组中不同药物处理对肝癌Huh-7细胞的生长抑制作用和计算每组药物的IC50值。成功构建人肝癌Huh-7细胞移植瘤模型，随机分为4组，1次/2 d给予尾静脉用药，连续2周，每周测量2次小鼠的体质量，测肿瘤的长径、短径。用药结束后处死小鼠，比较肿瘤的体积、质量，计算抑瘤率；HE染色法观察肿瘤组织病理学改变。结果131I-CD133mAb抗体标记率为90.25%，放射线化学纯度为97.78%；流式检测Huh-7细胞中CD133的表达为79.53%，明显高于HepG2细胞；免疫组化结果显Huh-7细胞CD133表达明显高于HepG2细胞；MTT法检测131I-CD133mAb+DDP组的细胞抑制率及体内抑瘤率明显高于131I-CD133mAb组、DDP组和空白对照组。结论131I-CD133mAb+DDP在体内体外能有效地抑制高表达CD133抗原的肝癌细胞生长。
목적：관찰131I-CD133mAb재체내외대고표체CD133항원적Huh-7인간암세포적파향억제작용。방법채용록알T법제비병감정131I-CD133mAb；류식검측Huh-7화HepG2세포중CD133적표체，면역조화검측류체내CD133적표체；실험설131I-CD133mAb여순박（cisplatin, DDP）련용조、131I-CD133mAb조、DDP조급공백대조조。MTT법검측각조중불동약물처리대간암Huh-7세포적생장억제작용화계산매조약물적IC50치。성공구건인간암Huh-7세포이식류모형，수궤분위4조，1차/2 d급여미정맥용약，련속2주，매주측량2차소서적체질량，측종류적장경、단경。용약결속후처사소서，비교종류적체적、질량，계산억류솔；HE염색법관찰종류조직병이학개변。결과131I-CD133mAb항체표기솔위90.25%，방사선화학순도위97.78%；류식검측Huh-7세포중CD133적표체위79.53%，명현고우HepG2세포；면역조화결과현Huh-7세포CD133표체명현고우HepG2세포；MTT법검측131I-CD133mAb+DDP조적세포억제솔급체내억류솔명현고우131I-CD133mAb조、DDP조화공백대조조。결론131I-CD133mAb+DDP재체내체외능유효지억제고표체CD133항원적간암세포생장。
Objective To study the inhibitory effect of CD133 monoclonal antibody labeled with 131I (131I-CD133mAb) on Huh-7 human liver cancer cell line overexpressing CD133 antigen in vitro and in mouse models bearing the tumor cell xenograft. Methods 131I-CD133mAb was prepared by chloramines-T method and evaluated for its stability. Flow cytometry and immunohistochemistry were used to detect the expression of CD133 in Huh-7 cells and in Huh-7 cell-derived tumors, respectively. Huh-7 cells treated with 131I-CD133mAb plus cisplatin (DDP), 131I-CD133mAb, DDP, or no treatment (blank control) were examined for cell proliferation suppression by MTT assay with the IC50 calculated. BALB/c mice bearing subcutaneous Huh-7 cell xenograft in the right forelegs were treated with 131I-CD133mAb, DDP, or both every two days for two weeks. The tumor size and volume were measured twice a week, and pathological examination of the tumor was carried out after the treatments. The tumor inhibition rate was calculated and tumor cell apoptosis observed with HE staining. Results The labeling ratio of 131I-CD133mAb was 90.25% and the radiochemical purity was 97.78%. Huh-7 cells showed obviously higher CD133 expression than HepG2 cells. 131I-CD133mAb combined with DDP group resulted in a significantly higher tumor inhibition rate than other treatments in the tumor-bearing mice. Conclusion 131I-CD133mAb can inhibit the growth of liver cancer cells with a high CD133 expression both in vivo and in vitro.